Lead Sponsor

AstraZeneca

Collaborators

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

No

•Diagnosed with type 2 diabetes.
•Have been exposed to exenatide for at least 3 months in previous Amylin/Lilly Studies H8O-MC-GWAO, H8O-MC-GWAP, H8O-MC-GWAT, or H8O-MC-GWBA.
•Have interrupted exenatide treatment for a period of at least 2 months.
•HbA1c of ≤10.5%.

•Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
•Have previously completed or withdrawn from this study.
•Have taken marketed exenatide (Byetta) during the interim period between studies GWAO, GWAP, GWAT, or GWBA and the current study.
•Used drugs for weight loss (for example, Xenical® \[orlistat\], Meridia® \[sibutramine\], Acutrim® \[phenylpropanolamine\], Accomplia® \[rimonabant\], or similar over-the-counter medications) within 3 months of screening.
•Are currently treated with any of the following excluded medications: Drugs that directly affect gastrointestinal motility, including, but not limited to: Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics.
•Use insulin with daily dosage exceeding 1 U/kg.